What is already known about this topic?
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants.
What is added by this report?
On August 3, 2023, the Advisory Committee on Immunization Practices recommended nirsevimab for infants aged <8 months born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk of severe RSV disease entering their second RSV season.
What are the implications for public health practice?
Nirsevimab can prevent severe RSV disease among infants and children aged <20 months at increased risk for severe RSV disease.
- United States of America